Ignite Creation Date:
2024-07-17 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06483334
Status:
RECRUITING
Last Update Posted:
2024-07-10
First Post:
2024-06-21
Brief Title:
A Study of Efficacy and Safety of Sacituzumab Tirumotecan MK-2870 Plus Enfortumab Vedotin EV With and Without Pembrolizumab in Advanced Urothelial Carcinoma MK-3475-04CKEYMAKER-U04
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-08-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-07-28
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-07-28
Completion Date Type:
ESTIMATED
First Submit Date:
2024-06-21
First Submit QC Date:
None
Study First Post Date:
2024-07-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-18
Last Update Post Date:
2024-07-10
Last Update Post Date Type:
ACTUAL